cyrilzakka/clinical-trials huggingface dataset:
Assessment of Intravenous Rate Control Response in Atrial Fibrillation Trial (AIRCRAFT)

The Assessment of Intravenous Rate Control Response in Atrial Fibrillation Trial Pilot Study (AIRCRAFT Pilot) is a prospective, unblinded, pragmatic, cluster-level allocation trial. AIRCRAFT compares two medication classes commonly used for rate control in patients in atrial fibrillation (AF) with rapid ventricular rate (RVR). The purpose of this pilot study is to evaluate the feasibility and approach to conducting a trial that compares the use of IV beta blockers and IV calcium channel blockers for patients in AF with RVR in the medical intensive care unit (MICU). AF with RVR is considered when the following parameters are met: (1) Cardiac rhythm consistent with AF (2) Heart rate \> 110 bpm. AF with RVR recurrence after conversion to sinus rhythm or prior rate control will count as a new episode of AF with RVR. Rate control agents will be pseudo-randomized to each of the three different MICU teams (beta-blocker, calcium channel blocker and physician preference). Patients are admitted to the three MICU teams on a rotating basis which will allow for pseudo-randomization, the effects of which will be equal between the three teams. Patients will be enrolled in the study if they develop AF with RVR and will be followed until discharge from the MICU. This study aims to assess the adherence and fidelity to treatment assignments in the current novel pilot study protocol which will help inform the feasibility of a larger-scale efficacy trial between IV beta blockers and IV calcium channel blockers for initial management of AF with RVR. Assessment of adherence and fidelity to treatment assignments in management of AF with RVR in the MICU will help inform power calculations and the percent of patients in each study group that received the assigned class of medication will help inform feasibility. Additional aims include assessment of time from medication administration to rate control or sinus conversion as well as identifying optimal means of data extraction (manual vs automated), and incidence of adverse events including hypotension and bradycardia.


Eligibility Criteria:
Inclusion Criteria:

* All adults admitted to the MICU at Boston Medical Center (BMC) during the study period who develop AF with RVR whose treating clinicians decides intravenous (IV) rate control agent is necessary to manage AF with RVR
* Patients readmitted to the MICU during the study period with recurrence of AF with RVR after conversion to sinus rhythm or prior rate control

Exclusion Criteria:

* Pregnancy
* Prisoners
* Allergies to study interventions
* Presentation consistent with acute asthma exacerbation
* Presentation consistent with acute systolic heart failure
Line Probe Assay Evaluation Study

This is a multi-center, blinded study to determine the performance of the YD Diagnostic Corporation (YD) REBA MTB-MDR® and Hain Genotype MTBDRplus V2 kit in a total of 600 clinical isolates and 900 residual sputum samples from patients with symptoms of pulmonary TB (PTB) and at risk of drug resistance. All testing was done on stored, de-identified leftover samples.

The study involved three World Health Organization (WHO) Supranational Reference Laboratories with well-characterized strain collections and access to sputum samples with significant rates of drug resistance.


Eligibility Criteria:
Inclusion Criteria:

* Age over 18 years
* Informed consent
* Patients evaluated for pulmonary TB

Exclusion Criteria:

-
Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke

Investigator-initiated prospective randomized multicentre study to uncover the true burden of paroxysmal atrial fibrillation in a representative population of acute stroke patients without known atrial fibrillation.


Eligibility Criteria:
Inclusion Criteria:

* Acute ischemic stroke or transitory ischemic attack (with clinical deficit on enrolment or MRI detected acute brain lesion on admission)
* Age ≥ 18 years
* Written or oral informed consent
* Stroke unit admission within 72 hours after stroke onset
* Start of standardized prolonged ECG monitoring within 24 hours after admission to the stroke unit
* Willingness to take part in the planned follow up examinations

Exclusion Criteria:

* Known atrial fibrillation
* Atrial fibrillation detected by ECG on admission
* Atrial fibrillation detected prior study enrollment on the stroke unit
* Life expectancy \< 1 year (before actual stroke)
* Life expectancy \< 1 month (after actual stroke)
* Indication for oral anticoagulation other than atrial fibrillation (e.g. mechanical heart valve)
* Severity level according National Institute of Health Stroke Scale (NIHSS) score \> 22
* Participation in an interventional trial
The People Like Us Evaluation Study

The study is a pragmatic, randomized controlled trial design to evaluate an online video series developed by a community-based organization in Singapore for gay, bisexual and queer men.

A total of 300 HIV-negative, gay, bisexual and queer men in Singapore aged 18 to 29 years old will be recruited with the assistance of the partner community-based organization (CBO), Action for AIDS Singapore. Recruitment will utilize both online and offline channels, and with the help of other CBOs in Singapore. Participants should also not have watched the video prior to their participation in this study, which will be ascertained through a questionnaire.

Participants will subsequently be randomized into the intervention arm (n=150) and the control arm (n=150). The treatment group (n=150) will be assigned the intervention along with sexual health information via a pamphlet, while the control group (n=150) will be assigned only the sexual health information via a pamphlet. This will be conducted through block randomization.


Eligibility Criteria:
Inclusion Criteria:

* Self-reported HIV-negative status, or unsure of HIV status
* Self-reported gay, bisexual or queer sexual orientation
* Self-reported male gender, regardless of sex assigned at birth
* Self-reported age of 18 to 29 years old at point of recruitment
* Singapore citizen or permanent resident at the point of recruitment
* Self-reported as never having watched an online video drama series by Gayhealth.sg or Action for AIDS in the last year

Exclusion Criteria:

* Participants who have watched the People Like Us Series prior to study
* Participants who have self-reported being HIV-positive
* Participants who are not English-literate
* Participants aged below 18 or above 29 at baseline recruitment
The Relation Between the Prognosis of Subthalamic Nucleus Deep Brain Stimulation Surgery by Microlesion Effect and Electrode Position

BACKGROUND: Parkinson's disease (PD) is a common movement disorder whose main symptoms include resting tremor, rigidity and bradykinesia. Deep Brain Stimulation (DBS) has become one of the most effective treatments for PD by implanting electrodes in specific deep brain nuclei to alleviate motor symptoms in PD patients. During the implantation of electrodes in the DBS procedure, small lesions produced are known as the Microlesion Effect, which disappears within a short period. The MLE efficacy is positively correlated with the overall efficacy of DBS, but whether the MLE efficacy is affected by the symptoms has not yet been investigated, and a large-sample study is needed to further validate this. This study aims to examine the relationship between electrode implantation location and the prediction of MLE efficacy produced by STN-DBS surgery in PD patients, assess the correlation between electrode implantation location and DBS efficacy in PD patients, and analyze the role of brain networks in the process. The study will also analyze the relationship between micro-destructive effects and long-term DBS efficacy, providing more effective efficacy prediction and a more accurate selection of electrode implantation locations for DBS treatment in PD patients. This study will guide the clinical practice of DBS treatment in PD patients and provide an important reference for future research in related fields.

Object: Primary Parkinson's Disease patients between the ages of 18 and 75 years who meet STN-DBS surgery criteria Aim: To observe the relationship between predicted efficacy and implantation location of STN-DBS for MLE in PD surgery


Eligibility Criteria:
Inclusion Criteria:

1. Idiopathic Parkinson Disease
2. Age from 18 to 80 years old
3. Performed bilateral STN-DBS

Exclusion Criteria:

1. Does not meet STN-DBS surgical criteria
2. Patients with severely offset electrode implantation position (imaging)
3. Not fulfilling the criteria for an arbitrary cohort under exposure conditions;
4. Patients who are unable to voluntarily sign an informed consent form;
5. Patients who do not agree to cooperate with follow-up visits
Performance of Neurally Adjusted Ventilatory Assist (NAVA) During Spontaneous Breathing Trial

The purpose of this study is to compare a new mode of mechanical ventilation (NAVA, or Neurally adjusted Ventilatory assist) with a traditional mode (Pressure Support ventilation) on its the ability to detect patients ready for extubation (liberation from mechanical ventilation).

Patients under mechanical ventilation who are suspected to be recovered and ready to return to spontaneous ventilation often undergo an spontaneous breathing trial (SBT) before extubation and liberation from mechanical ventilation. During the test, which lasts from 30 minutes to 2 hours , the patient receives minimal support from the ventilator, and the ICU team observes if the patient develops any signs or symptoms of discomfort or respiratory distress. If the patient tolerates the test, he or she is considered ready for extubation. The Neurally Adjusted Ventilatory Assist (NAVA) is a new mode of ventilation, shown to improve patient-ventilator synchrony. It has not been tested during SBTs. Our objective is to compare the performance of NAVA with the commonly used Pressure Support ventilation, during an SBT. Patients considered to be ready for an SBT by the ICU team will undergo two SBTs in random order: one in pressure support, and the other on NAVA, with a 1-hour interval between the tests. Ventilatory parameters and patient-ventilator interaction variables will be compared among the two tests.

This study will help us understand if NAVA can be used during an SBT, which might be important for patients who are being ventilated with NAVA before the SBT is suggested, especially those how present a high asynchrony rate when ventilated with Pressure Support Mode.

Eligibility Criteria:
Inclusion Criteria:

* mechanical ventilation for more than 48 hours
* Considered ready for an spontaneous breathing trial by the ICU team
* informed consent for participation on the study signed by a family member

Exclusion Criteria:

* age \< 18yrs
* pregnancy
* facial trauma or burns that might interfere with the esophageal catheter placement
* nasal pathologies that prevent adequate placement of the catheter
* esophageal varices or gastroesophageal bleeding in the past 30 days
Study of the Satiating Properties of a Hybrid Protein Snack Mainly From Chickpeas

A randomized, crossover and controlled clinical trial will be developed in 23 individuals to evaluate the postprandial effect of consuming snacks rich in vegetable and animal protein compared to a high-quality pork sausage

A randomized, crossover and controlled clinical trial will be developed in 23 individuals to evaluate the postprandial effect of consuming snacks rich in vegetable and animal protein compared to a high-quality pork sausage. Each of the participants will consume the two types of snacks (20 grams) following a random assignment order. The design is randomised and cross-over.

A greater satiating effect is expected with the hybrid snack, given that the fiber in chickpea flour is higher than that of dry chickpeas. In addition, chickpea flour is rich in soluble fiber (a type of fiber that helps retain water and therefore slows down digestion) having positive effects on the gastrointestinal tract and on the metabolism of LDL cholesterol, as well as on blood glucose .

Foods high in complex carbohydrates and fiber have a satiating effect due to their fiber content. It is known that the most satiating macronutrient is protein if the food also contains fiber, this favors that some nutrients are not fully absorbed, including fat. Hence, these foods have a satiety index greater than fat itself, thus favoring adherence to diet and body weight, since it is possible to control portions, avoiding snacking on unhealthy products.

Eligibility Criteria:
Inclusion Criteria:

* 23 participants between 18 and 30 years old, with a ratio between men and women of approximately 50%.

Exclusion Criteria:

* Diabetics
* Chronic medication except contraceptives
* Diagnosis of inflammatory bowel disease (IBD)
* Any serious active disease that prevents or disables to adequately follow the study
* Regular cannabis users
* Alcoholism or active drug dependence
* Inability to give informed consent
* Pregnancy and lactation
* Intolerance to any of the components of the two snack which are intended to be tested
A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.

This single arm study will assess the efficacy and safety of Xeloda in combination with oxaliplatin as first-line chemotherapy in patients with advanced and/or metastatic gastric cancer who have had no prior chemotherapy for advanced or metastatic disease. Eligible patients will receive Xeloda 1000mg/m2 po twice daily, D1-D10 every 2 weeks (10 days treatment followed by 4 days rest period) plus oxaliplatin 85 mg/m2/day iv, D1 every 2 weeks. The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.


Eligibility Criteria:
Inclusion Criteria:

* adult patients, \>=18 years of age;
* gastric cancer with unresectable locally advanced and/or metastatic disease;
* \>=1 measurable lesion;
* ambulatory, with ECOG Performance Status \>=1.

Exclusion Criteria:

* previous chemotherapy (except adjuvant or neoadjuvant treatment \>=6 months prior to enrollment);
* clinically significant cardiac disease or myocardial infarction within last 12 months;
* CNS metastases;
* history of other malignancy within last 5 years, except for cured basal cell cancer of the skin, or in situ cancer of the cervix.
Spread of Dermatophytes Among Families

The objective is to demonstrate person-to-person spread of dermatophytes of the skin and nails among family members, as measured by fungal culture and DNA typing of the dermatophytes isolated.

Enrolled families consist of at least two members over the age of 14. Once the index person is examined and a dermatophyte is isolated from either toenail or foot scale, other family members are examined and cultured. All dermatophyte isolates obtained from each family unit are compared using DNA typing and restriction length polymorphism (RFLP) to determine whether family members share the same organism or were infected by an outside source.

Eligibility Criteria:
Inclusion Criteria: positive dermatophyte culture

-

Exclusion Criteria:

* use of antifungal agents, either oral or topical
A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C

A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation

This is a Phase 2, multi-center, open-label study. Up to sixty subjects with irritable bowel syndrome with constipation who are between the ages of 18 and 65, inclusive, will be enrolled. Subjects must have completed the previous SB-2-010-001 study. The entire duration of the study may be up to 57 days (from enrollment to the post end-of-study \[EOS\] visit telephone call).

Eligibility Criteria:
Inclusion Criteria:

* Subject has completed Study SB-2-010-001.
* Subject must be willing to abstain from or discontinue the use of any laxatives and any prescription and over-the-counter medications or supplements intended to treat constipation from the time of Screening to the end of the study, except as permitted in this protocol.
* Subject must agree to refrain from making any lifestyle changes that may affect IBS-C symptoms from the time of Screening to the end of the study.

Exclusion Criteria:

* Subject has taken IBS treatments (prescription or over-the-counter), proton pump inhibitors, laxatives, antibiotics.
* Subject did not complete Study SB-2-010-001 or more than 7 days have elapsed since the subject's last dose of study drug in that study.
* Subject reports loose (mushy) or watery stools (Bristol Stool Form Scale \[BSFS\] score of 6 or 7) in the absence of any laxative, or has a BSFS score of 6 for more than 1 spontaneous bowel movement (SBM) or a BSFS score of 7 for any SBM during the last 7 days of diary reporting for Study SB-2-010-001.
* Subject has any abnormal laboratory results, electrocardiogram (ECG) findings, or physical examination findings deemed clinically significant by the investigator at the Study SB-2-010-001 End-of-Study Visit.
ARTIFICIAL INTELLIGENCE IN REPRODUCTIVE MEDICINE

Many studies have been published investigating the use of AI as an unbiased, automated approach to embryo assessment. This review will summarize the recent AI advancements in the IVF field. Hopefully, that incorporating AI technology into the IVF clinics may be the next frontier in the journey towards personalised reproductive medicine and improved fertility outcomes for patients.

ARTIFICIAL INTELLIGENCE (AI) APPLICATIONS IN REPRODUCTIVE MEDICINE

Kamaleldin Abdullah Rageh, M.D. (1).

Mohammad Atef Behery, M.D. (2)

Elsayed Ali Farag, M.D. (1)

1 -Department of Obstetrics and Gynecology, Faculty of medicine, Al-Azhar University, Cairo, Egypt.

2-International Islamic Center for Population Studies and Research, Al-Azhar University, Cairo, Egypt.

Abstract:

In spite of improved almost all aspects of IVF: ovarian stimulation, embryo culture and transfer, the pregnancy rates still not satisfactory. Studies confirm that up to 50% of the performed IVF cycles fail and there may be no direct explanation for this.

And it's worthy to mention that accurately predicting the outcome of an IVF cycle has yet to be achieved. One reason for this is the method of selecting an embryo for transfer. Morphological assessment of embryos is the traditional method of evaluating embryo quality and selecting which embryo to transfer. However, this subjective method of assessing embryos leads to inter- and intra-observer variability, resulting in less than optimal IVF success rates. Although time-lapse incubators and preimplantation genetic testing for aneuploidy have been introduced to help increase the chances of live birth, the outcomes remain less than ideal.

Currently, infertility treatments exert a lot of financial and emotional stress, especially in patients with previously failed IVF treatments, where there is no clear cause to be identified is a common, heartbreaking endpoint when the emotional, financial and physical burden of the treatment escalate to continue finding answers, but AI systems might help solve the dilemma by picking the best viable embryos that humans can't do. AI technologies have excellent potential to help the infertility field to soar over its current narrow focus on individual embryos and detect new patterns hidden in the patient data for overcoming the prevailing infertility cases.

The embryo selection is the most critical factor for the success of IVF. However, there is no single definitive criterion that can predict the success of an embryo. Rather, embryo selection is based on a variety of factors, making it is difficult to predict the probability of a successful pregnancy for each patient and to fully understand the cause of each failure. So, Utilization of artificial intelligence (AI) may support the clinicians in filling this knowledge gap, thereby being leveraged in the embryology laboratory to help improve IVF outcomes.

Eligibility Criteria:
Inclusion Criteria:

* fertility related

Exclusion Criteria:

* fertile people
AI-Driven Prediction of Dialysis Outcome With EHR

This is a multi-center, clinical study designed to evaluate the application and effectiveness of an AI-assisted predictive model for outcome of dialysis patients, leveraging multimodal health data.

This study aims to develop an AI-assisted model to predict clinical outcomes in dialysis patients, focusing on both primary outcomes (e.g., mortality) and intermediate outcomes (e.g., anemia, blood pressure, nutritional status, and calcium-phosphate metabolism). The study will utilize patients' EHR data, including laboratory test results, medical history, dialysis treatment information, and clinical observations, to predict these health outcomes. The goal is to improve early identification of at-risk patients, enabling better clinical decision-making and personalized care strategies.

Eligibility Criteria:
Inclusion Criteria:

1. Patients who have been undergoing dialysis (either hemodialysis or peritoneal dialysis) for at least 3 months.
2. Complete and accessible EHR data, including medical history, laboratory test results, dialysis treatment details, and clinical observations.
3. Participants must provide informed consent for the use of their health data for research purposes.

Exclusion Criteria:

1. Patients with incomplete or missing critical EHR data, including medical history, laboratory results, dialysis data, or treatment details necessary for the study.
2. Patients who have been on dialysis for less than 3 months, to ensure stable data for outcome prediction.
Consequences of Post Stroke Polysomnographic Abnormalities on Functionnal Recovery and Survival After an Ischemic Stroke

Ischemic stroke is a major public health issue, likely to cause functional disability. It is well known that sleep has an impact on brain plasticity, and after an ischemic stroke, studies have shown subjective sleep quality alterations and sleep architecture abnormalities.

Furthermore, there is no clear guideline showing the usefulness of a systematic sleep investigation following an ischemic stroke.

The aim of the study is to identify retrospectively correlation between polysomnographic abnormalities (sleep apnea, periodic limb movements, disturbed sleep architecture...) and functional recovery after an ischemic stroke. The study also assesses the impact of sleep abnormalities on survival, and the risk of new cardiovascular event.

This study is a retrospective observational study, from a cohort of patients who had a sleep recording (polysomnography or ventilatory polygraphy performed in Montpellier University Hospital) following an ischemic stroke.

Eligibility Criteria:
Inclusion criteria:

* men and women, more than 18 years old
* medical history of ischemic stroke
* who had a sleep recording following the stroke

Exclusion criteria:

* others types of strokes (bleeding, transient ischemic attack, cerebal veinous thrombosis)
* patients less than 18 years old